Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest announcement is out from VentriPoint Diagnostics ( (TSE:VPT) ).
Ventripoint Diagnostics has strengthened its sales strategy by appointing Karl Pringle to its Business Advisory Board, aiming to drive global growth of its VMS+ technology by 2025. With Pringle’s extensive experience in healthcare technology and proven track record in driving sales and transformation, the company is poised to expand its market presence and accelerate adoption of its innovative cardiac diagnostic solutions.
More about VentriPoint Diagnostics
Ventripoint Diagnostics Ltd. operates in the healthcare technology industry, specializing in AI-powered heart-scanning solutions. Their primary product, the VMS+ platform, enhances echocardiography and offers a cost-effective alternative to traditional MRI scans, aiming to make cardiac diagnostics more accessible globally.
YTD Price Performance: -18.33%
Average Trading Volume: 150,149
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$15.41M
For a thorough assessment of VPT stock, go to TipRanks’ Stock Analysis page.
